View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 9, 2021

Rokote Laboratories Finland to unveil new nasal vaccine for Covid-19

Rokote Laboratories Finland Ltd is set to launch a nasal spray Covid-19 vaccine that uses gene transfer technology.

By Vishnu Priyan

Rokote Laboratories Finland Ltd is set to launch a nasal spray Covid-19 vaccine that uses gene transfer technology.

Developed at the University of Eastern Finland by the research group of academy professor Seppo Ylä-Herttuala, the technology has already been used in several clinical trials successfully with gene therapy to treat cardiovascular diseases and cancer.

The nasal spray vaccine is based on research conducted at the University of Helsinki (UHEL) and the University of Eastern Finland (UEF).

It uses a safe adenovirus carrier with a cloned DNA strand, which causes nasopharyngeal cells to make the virus protein, producing a vaccine response.

According to preliminary results, the vaccine has worked well in animal studies and is set to enter clinical testing in humans in a few months.

As the virus naturally transmits through the airways, the nasal delivery method was selected as the new vaccine’s administration mode.

Furthermore, nasal administration could potentially produce a broader immune response, as noticed with intramuscular administration.

Professor Ylä-Herttuala said: “Vaccines injected intramuscularly produce IgG antibodies in the bloodstream, but nasal vaccines also produce an IgA response that protects mucous membranes.

“We assume that this can also prevent those who have received the vaccine from transmitting the virus.”

Rokote Laboratories intends to conduct the first clinical vaccine trials in Finland. Commercial technology needed to manufacture the vaccine is already available in Kuopio.

On another note, Baxter International (BAX) has signed an agreement to offer fill-and-finish sterile manufacturing services and supply packaging for 60 to 90 million doses of the Moderna Covid-19 vaccine this year.

Baxter BioPharma Solutions (BPS) will be responsible for these services.

The company will manufacture the vaccine at its fill-and-finish sterile manufacturing facilities in Bloomington, Indiana.

The companies have not divulged further details of the deal.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology